Strategic Asset: National Pharmaceutical Litigation Brand - Inquire Below
Established 1999 • 2026 Litigation Status: ACTIVE

DIET DRUG CASE

The National Nexus for GLP-1 & Pharmaceutical Tort Case Generation

Qualified Litigation Focus Areas

Verified Gastroparesis

Chronic stomach paralysis confirmed via GES or breath scintigraphy tests.

NAION Vision Loss

Irreversible optic nerve damage (Eye Stroke) resulting in blindness.

Ileus & Obstruction

Bowel paralysis or intestinal blockages requiring surgical intervention.

Gallbladder Disease

Severe cholecystitis resulting in cholecystectomy (removal) surgery.

Deep Vein Thrombosis

Emerging research links semaglutides to increased risks of DVT and PE.

Failure to Warn

Litigation focused on the duty to disclose risks of permanent dysfunction.

Nationwide Jurisdictional Reach

Centralized intake for all 50 states and major hubs:

Philadelphia (MDL Hub) Dallas Miami Chicago Los Angeles Houston Atlanta New York

ACQUISITION & INTAKE PROTOCOL